Expression and significance of OX40/OX40L in peripheral blood of patients with autoimmune hepatitis,primary biliary cholangitis,and their overlap syndrome

WANG WeiZhao; ZHU QinLing; XIANG XiaoXing; MA Li; GU Da; TONG Cong; WANG TingTing; HE JiaJun; LIU Jun; WANG Lu; CHEN ChaoWu

doi:10.3969/j.issn.1001-5256.2020.12.020

Volume 36 Issue 12

Dec. 2020

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2020 > 36(12): 2740-2745

PDF( 1389 KB)

Expression and significance of OX40/OX40L in peripheral blood of patients with autoimmune hepatitis,primary biliary cholangitis,and their overlap syndrome

DOI: 10.3969/j.issn.1001-5256.2020.12.020

Center of Endoscopic Diagnosis and Treatment,Subei People's Hospital of Jiangsu & Clinical Medical College of Yangzhou University
Department of Gastroenterology,Subei People's Hospital of Jiangsu & Clinical Medical College of Yangzhou University
Graduate School,Dalian Medical University
Center of Rheumatology and Immunology,Subei People's Hospital of Jiangsu & Clinical Medical College of Yangzhou University

Received Date: 2020-06-10
Published Date: 2020-12-20

Abstract

Abstract

Objective To investigate the expression and clinical significance of OX40/OX40 L( CD134/CD134 L) in CD4 + T cells,CD8 +T cells,monocytes,and B lymphocytes in peripheral blood of patients with autoimmune hepatitis( AIH),primary biliary cholangitis( PBC),and their overlap syndrome before and after standardized treatment. Methods A total of 74 patients with AIH,PBC,and their o-verlap syndrome who were diagnosed in Subei People's Hospital of Jiangsu from August 2015 to August 2019 were enrolled,and according to related diagnostic criteria,they were divided into AIH group( group A) with 29 patients,PBC group( group P) with 26 patients,and overlap syndrome group( group C) with 19 patients. A healthy control group with 30 individuals was also established. Peripheral blood samples were collected before and after standardized treatment to measure the expression of OX40/OX40 L on the surface of peripheral blood cells by immunofluorescence flow cytometry,and the expression of OX40/OX40 L was compared before and after treatment and between the three groups and the healthy control group to investigate its clinical significance. A one-way analysis of variance was used for comparison between multiple groups,and the least significant difference t-test was used for further comparison between two groups; the paired t-test was used for comparison of paired samples between two groups. Results There were no significant differences in sex composition and age composition between the three groups( P > 0. 05). Before treatment,the positive rate of OX40 in peripheral blood CD4+T cells gradually increased in groups A,P,and C,and groups A,P,and C had a significantly higher positive rate of OX40 than the control group( 14. 80% ± 4. 99%/17. 11% ± 2. 71%/25. 18% ± 5. 55% vs 6. 67% ± 2. 26%,F = 14. 823,P < 0. 001); groups A,P,and C had a significantly higher positive rate of OX40 in CD8+T cells than the control group( 4. 86% ± 1. 54%/6. 40% ± 1. 88%/7. 33% ± 2. 12% vs 4. 09% ± 2. 69%,F =5. 486,P < 0. 001); the positive rate of OX40 L in CD14+monocytes was 19. 84% ± 6. 11% in group A,21. 17% ± 4. 35% in group P,29. 13% ± 6. 32% in group C,and 4. 86% ± 2. 34% in the control group,and there was a significant difference between groups( F =17. 004,P < 0. 001); the positive rate of OX40 L in CD19+B cells was 17. 62% ± 3. 86% in group A,14. 75% ± 4. 32% in group P,10. 13% ± 2. 56% in group C,and 4. 50% ± 1. 38% in the control group,showing a trend of gradual reduction,and groups A,P,and C had a significantly higher positive rate than the control group( F = 12. 221,P < 0. 001). After treatment,the positive rate of OX40 in CD8+T cells decreased significantly to a similar level as the control group,and there was no significant difference between groups( F =0. 731,P = 0. 538). For the other three types of cells,although there were varying degrees of reduction in the positive rate of OX40/OX40 L after treatment,groups A,P,and C still had a significantly higher positive rate than the control group; in CD4+T cells,the positive rate of OX40 was 11. 00% ± 1. 98% in group A,13. 72% ± 1. 03% in group P,19. 72% ± 3. 47% in group C,and 6. 67% ± 2. 26% in the control group,and groups A,P,and C had a significantly higher positive rate than the control group( F = 11. 365,P < 0. 001); in CD14+monocytes,the positive rate of OX40 L was 11. 82% ± 2. 23% in group A,15. 19% ± 4. 42% in group P,24. 51% ± 4. 09% in group C,and 4. 86% ± 2. 34% in the control group,and groups A,P,and C had a significantly higher positive rate than the control group( F =13. 748,P < 0. 001); in CD19+B cells,the positive rate of OX40 L was 9. 09% ± 3. 25% in group A,6. 81% ± 2. 20% in group P,7. 48% ± 2. 85% in group C,and 4. 50% ± 1. 38% in the control group,and groups A,P,and C had a significantly higher positive rate than the control group( F = 8. 052,P < 0. 001). Groups A,P,and C had significant reductions in the expression of OX40/OX40 L in peripheral blood CD4+T cells,CD8+T cells,CD14+monocytes,and CD19+B lymphocytes after treatment( all P < 0. 05). Conclusion The expression of OX40/OX40 L in peripheral blood increases in patients with AIH,PBC,and their overlap syndrome and decreases after treatment,indicating that the OX40/OX40 L pathway is involved in the pathogenesis of the above diseases,and the role of OX40 on the surface of CD8+T cells may better reflect the treatment outcome.
- hepatitis,autoimmune,
- primary biliary cholangitis,
- overlap syndrome,
- receptors,OX40,
- OX40 ligand

FullText(HTML)

References(24)

References

[1] LLEO A,LEUNG P,HIRSCHFIELD GM,et al. The pathogenesis of primary biliary cholangitis:A comprehensive review[J].Semin Liver Dis,2020,40(1):34-48.

[2] ARNDTZ K,HIRSCHFIELD GM. The pathogenesis of autoimmune liver disease[J]. Dig Dis,2016,34(4):327-333.

[3] SEBODE M,HARTL J,VERGANI D,et al. Autoimmune hepatitis:From current knowledge and clinical practice to future research agenda[J]. Liver Int,2018,38(1):15-22.

[4] WILLOUGHBY J,GRIFFITHS J,TEWS I,et al. OX40:Structure and function-What questions remain?[J]. Mol Immunol,2017,83:13-22.

[5] DENG J,ZHAO S,ZHANG X,et al. OX40(CD134)and OX40 ligand,important immune checkpoints in cancer[J].Onco Targets Ther,2019,12:7347-7353.

[6] LEI W,ZENG D,LIU G,et al. Crucial role of OX40/OX40L signaling in a murine model of asthma[J]. Mol Med Rep,2018,17(3):4213-4220.

[7] WEBB GJ,HIRSCHFIELD GM,LANE PJ. OX40,OX40L and autoimmunity:A comprehensive review[J]. Clin Rev Allergy Immunol,2016,50(3):312-332.

[8] HENNES EM,ZENIYA M,CZAJA AJ,et al. Simplified criteria for the diagnosis of autoimmune hepatitis[J]. Hepatology,2008,48(1):169-176.

[9] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Infectious Diseases,Chinese Medical Association. Consensus on the diagnosis and management of primary biliary cirrhosis(cholangitis)(2015)[J]. J Clin Hepatol,2015,31(12):1980-1988.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会．原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015)[J]．临床肝胆病杂志，2015,31(12):1980-1988.

[10] CHAZOUILLRES O,WENDUM D,SERFATY L,et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome:Clinical features and response to therapy[J]. Hepatology,1998,28(2):296-301.

[11] ALVAREZ F,BERG PA,BIANCHI FB,et al. International Autoimmune Hepatitis Group Report:Review of criteria for diagnosis of autoimmune hepatitis[J]. J Hepatol,1999,31(5):929-938.

[12] LIU F,PAN ZG,YE J,et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome:Simplified criteria may be effective in the diagnosis in Chinese patients[J]. J Dig Dis,2014,15(12):660-668.

[13] PATERSON DJ,JEFFERIES WA,GREEN JR,et al. Antigens of activated rat T lymphocytes including a molecule of 50,000Mr detected only on CD4 positive T blasts[J]. Mol Immunol,1987,24(12):1281-1290.

[14] WANG WZ,XIANG XX. Immunological mechanism of Treg/Th17and Th1/Th2 balance in autoimmune hepatitis and new targets for diagnosis and treatment[J]. J Clin Hepatol,2019,35(8):1874-1877.(in Chinese)王维钊，向晓星．Treg/Th17、Th1/Th2平衡在自身免疫性肝炎中的免疫学机制及诊疗新靶点[J]．临床肝胆病杂志，2019,35(8):1874-1877.

[15] UENO H,BLANCO P. OX40/OX40L axis:Not a friend in autoimmunity[J]. Oncotarget,2015,6(26):21779-21780.

[16] MIELI-VERGANI G,VERGANI D,CZAJA AJ,et al. Autoimmune hepatitis[J]. Nat Rev Dis Primers,2018,4:18017.

[17] LIANG M,LIWEN Z,YUN Z,et al. The imbalance between Foxp3+Tregs and Th1/Th17/Th22 cells in patients with newly diagnosed autoimmune hepatitis[J]. J Immunol Res,2018,2018:3753081.

[18] NAKAGAWA R,MUROYAMA R,SAEKI C,et al. CD4+T cells from patients with primary biliary cholangitis show T cell activation and differentially expressed T-cell receptor repertoires[J]. Hepatol Res,2019,49(6):653-662.

[19] WEBB GJ,HIRSCHFIELD GM,KRAWITT EL,et al. Cellular and molecular mechanisms of autoimmune hepatitis[J]. Annu Rev Pathol,2018,13:247-292.

[20] SITRIN J,SUTO E,WUSTER A,et al. The Ox40/Ox40 ligand pathway promotes pathogenic th cell responses,plasmablast accumulation,and lupus nephritis in NZB/W F1 Mice[J]. J Immunol,2017,199(4):1238-1249.

[21] JIANG J,LIU C,LIU M,et al. OX40 signaling is involved in the autoactivation of CD4+CD28-T cells and contributes to the pathogenesis of autoimmune arthritis[J]. Arthritis Res Ther,2017,19(1):67.

[22] MIAO Q,BIAN Z,TANG R,et al. Emperipolesis mediated by CD8 T cells is a characteristic histopathologic feature of autoimmune hepatitis[J]. Clin Rev Allergy Immunol,2015,48(2-3):226-235.

[23] HIPPCHEN T,SAUER P,GPPERT B,et al. Association between serum IgG level and clinical course in primary sclerosing cholangitis[J]. BMC Gastroenterol,2019,19(1):153.

[24] BRAHIM I,BRAHIM I,HAZIME R,et al. Autoimmune hepatitis:Immunological diagnosis[J]. Presse Med,2017,46(11):1008-1019.

Relative Articles

[1]	Jialuo WANG, Yufeng ZHENG, Qingfang XIONG, Yongfeng YANG. Etiology spectrum， clinical features， and gene mutations of unexplained intrahepatic cholestasis： An analysis of 62 cases[J]. Journal of Clinical Hepatology, 2025, 41(2): 307-313. doi: 10.12449/JCH250217
[2]	Sa LYU, Bing ZHU, Tianjiao XU, Shaoli YOU. The extreme reduction in cholinesterase caused by compound heterozygous mutations in the BCHE gene： A case report[J]. Journal of Clinical Hepatology, 2024, 40(10): 2075-2078. doi: 10.12449/JCH241023
[3]	Yuanzhi HUANG, Fuchuan WANG, Yi DONG, Zhiqiang XU, Yinjie GAO, Jianguo YAN, Lili CAO, Danni FENG, Min ZHANG. Liver disease phenotypes and clinical features of patients with different genotypes of Wilson’s disease[J]. Journal of Clinical Hepatology, 2024, 40(8): 1627-1632. doi: 10.12449/JCH240819
[4]	Wendi LIU, Peng WANG, Heping HU, Huabang ZHOU. ABCB4 gene mutation-associated liver cirrhosis with gallstones： A case report[J]. Journal of Clinical Hepatology, 2024, 40(3): 585-588. doi: 10.12449/JCH240324
[5]	Aierkenjiang MALIPATI, Kuerban KAIDIRIYA, Ling XU, Xiaofeng SUN. Research advances in the pathogenesis, phenotype-genotype relationship, and pharmacotherapy of hepatolenticular degeneration[J]. Journal of Clinical Hepatology, 2023, 39(6): 1497-1504. doi: 10.3969/j.issn.1001-5256.2023.06.037
[6]	Shuduo WU, Yibo ZHAN, Xinhua LI, Changlei XU, Minling CAO, Xiaoling CHI. Hereditary hemochromatosis with multiple organ damage caused by HJV gene mutation in adults: A case report[J]. Journal of Clinical Hepatology, 2022, 38(11): 2571-2574. doi: 10.3969/j.issn.1001-5256.2022.11.026
[7]	Dan YANG, Cuiwei ZHANG, Mingming DENG. A compound heterozygous mutation in the ATP7B gene with acute fatty liver of pregnancy: A case report[J]. Journal of Clinical Hepatology, 2022, 38(1): 167-169. doi: 10.3969/j.issn.1001-5256.2022.01.027
[8]	Bo YI, Xue LI, Shanhong TANG. Research advances in the mechanism of abnormal bile acid metabolism caused by gene mutation[J]. Journal of Clinical Hepatology, 2022, 38(9): 2136-2140. doi: 10.3969/j.issn.1001-5256.2022.09.036
[9]	Chengyu ZHU, Qi CHEN, Zhongxin FENG. Hereditary hemochromatosis caused by mutation in the SLC40A1 gene: A case report[J]. Journal of Clinical Hepatology, 2021, 37(5): 1180-1182. doi: 10.3969/j.issn.1001-5256.2021.05.041
[10]	Yong ZHANG, Zhengfa MAO. Association of tuberous sclerosis gene 1/2 mutations with the progression of hepatocellular carcinoma and prognosis[J]. Journal of Clinical Hepatology, 2021, 37(1): 84-88. doi: 10.3969/j.issn.1001-5256.2021.01.017
[11]	Lei HUA, Quan SUN, Wenbin XU, Long ZHANG, Gongqiang WANG. ABCB4 gene mutation-associated liver cirrhosis misdiagnosed as Wilson's disease: A case report[J]. Journal of Clinical Hepatology, 2021, 37(6): 1419-1420. doi: 10.3969/j.issn.1001-5256.2021.06.039
[12]	Liang Chen, Bai Li, Zheng SuJun. Research advances in mutation characteristics of the UGT1A1 gene in Gilbert syndrome and its influence on intrahepatic and extrahepatic systems[J]. Journal of Clinical Hepatology, 2019, 35(7): 1632-1635. doi: 10.3969/j.issn.1001-5256.2019.07.046
[13]	Li Ning, Zhang Xin, Li Rui, Jiao Lin. Hepatolenticular degeneration with MTHFR gene mutation: A case report[J]. Journal of Clinical Hepatology, 2019, 35(11): 2549-2550. doi: 10.3969/j.issn.1001-5256.2019.11.033
[14]	Liang Chen, Bai Li, Zheng SuJun. Research advances in the genotype-phenotype correlation, diagnosis, treatment, and screening of Wilson's disease[J]. Journal of Clinical Hepatology, 2019, 35(9): 2116-2119. doi: 10.3969/j.issn.1001-5256.2019.09.052
[15]	Pang Ting, Xing HuiChun. Correlation between drug-resistance gene mutations and hepatocellular carcinoma in patients with hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2017, 33(1): 82-86. doi: 10.3969/j.issn.1001-5256.2017.01.017
[16]	Lu: TingXia, Zhang Wei, Li XiaoJin, Xu AnJian, Zhao XinYan, Ou XiaoJuan, Huang Jian. Characteristics of gene mutation in Chinese patients with hereditary hemochromatosis[J]. Journal of Clinical Hepatology, 2016, 32(8): 1571-1574. doi: 10.3969/j.issn.1001-5256.2016.08.028
[17]	Hu AiRong, Hu Ting. Common mutations of hepatitis B virus and their clinical significance[J]. Journal of Clinical Hepatology, 2016, 32(8): 1463-1467. doi: 10.3969/j.issn.1001-5256.2016.08.006
[18]	Mao WeiWu, Du Peng, Zhang WenJie, Li Jing, Qu Yan, Shi HuaiYuan, Wang YanXia. Impact of HCV 5′NCR genetic mutation on standard program of anti-HCV therapy[J]. Journal of Clinical Hepatology, 2015, 31(4): 585-587. doi: 10.3969/j.issn.1001-5256.2015.04.026
[19]	Su Zheng, Yao XiXian, Wang JunMin, Bai WenYuan, Zhang XinYuan. The relationship between the levels of serum IL-4 and IFN-γ and influence factors of anti-viral therapy for patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2007, 23(3): 185-186.

Supplements(0)

Cited By

Cited by

Periodical cited type(4)

1.	周文强，黄曦，占魁. 异甘草酸镁联合替诺福韦治疗病毒性肝炎的效果及对肝功能的影响. 临床合理用药. 2025(05): 90-92 .
2.	陈晖蓉，李晓晴. 索磷布韦维帕他韦治疗基因2a型肝炎的疗效分析. 中外医疗. 2024(16): 71-74+78 .
3.	唐茂芝，张克勤. HCV阴性受者接受HCV阳性供肾肾移植临床研究现状. 器官移植. 2023(02): 235-240 .
4.	张特，李红磊，黄强. 索非布韦联合雷迪帕韦治疗丙型病毒性肝炎的疗效观察. 实用中西医结合临床. 2023(03): 46-48+66 .

Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (4269) PDF downloads(71)

Expression and significance of OX40/OX40L in peripheral blood of patients with autoimmune hepatitis,primary biliary cholangitis,and their overlap syndrome

DOI: 10.3969/j.issn.1001-5256.2020.12.020